Akagera Medicines
Kigali, Rwanda· Est.
Rwanda‑based biotech delivering liposomal long‑acting injectables for TB and infectious disease vaccines.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Rwanda‑based biotech delivering liposomal long‑acting injectables for TB and infectious disease vaccines.
Infectious DiseasesVaccines
Technology Platform
Patented liposomal nanocarriers for long‑acting injectable delivery of antibacterial drugs and antigens, targeting macrophage uptake and sustained release.
Opportunities
Successful Phase I data could unlock large‑scale funding and licensing deals for TB and vaccine programs, positioning Akagera as a key player in African infectious‑disease therapeutics.
Risk Factors
Regulatory approval timelines, scale‑up manufacturing challenges, and competition from established TB drug developers could delay commercialization.
Competitive Landscape
Competitors include TB Alliance, Janssen, and other biotech firms developing novel TB regimens; Akagera differentiates through its liposomal long‑acting injectable platform and African‑focused ownership model.